Nektar Therapeutics (FRA:ITH)

€ 1.202 0.052 (4.52%) Market Cap: 237.00 Mil Enterprise Value: 90.66 Mil PE Ratio: 0 PB Ratio: 3.09 GF Score: 60/100

Q2 2024 Nektar Therapeutics Earnings Call Transcript
Aug 08, 2024

€1.06 (-0.47%)

Earnings
Q4 2023 Nektar Therapeutics Earnings Call Transcript
Mar 04, 2024

€0.7252 (+12.23%)

Earnings
Nektar Therapeutics at JPMorgan Healthcare Conference Transcript
Jan 11, 2024
Q3 2023 Nektar Therapeutics Earnings Call Transcript
Nov 07, 2023

€0.501 (-0.52%)

Earnings
Nektar Therapeutics to Host Virtual Investor & Analyst Event Transcript
Sep 13, 2023
Q2 2023 Nektar Therapeutics Earnings Call Transcript
Aug 08, 2023

€0.916 (-6.09%)

Earnings
Nektar Therapeutics at Goldman Sachs Healthcare Conference Transcript
Jun 14, 2023
Q1 2023 Nektar Therapeutics Earnings Call Transcript
May 09, 2023

€0.688 (-6.60%)

Earnings
Nektar Therapeutics Analyst and Investor Call Transcript
Feb 23, 2023
Nektar Therapeutics at JPMorgan Healthcare Conference Transcript
Jan 11, 2023
Nektar Therapeutics To Host Investor & Analyst Event Transcript
Dec 12, 2022
Q3 2022 Nektar Therapeutics Earnings Call Transcript
Nov 03, 2022

€3.69 (-3.95%)

Earnings
Q2 2022 Nektar Therapeutics Earnings Call Transcript
Aug 04, 2022

€4.38 (+0.97%)

Earnings
Nektar Therapeutics Corporate Call for Analysts and Investors to Outline New Strategic Plan Transcript
Apr 25, 2022
Nektar Therapeutics to Host Webcast Conference Call for Analysts & Investors Following Announcement of Update from Bristol-Myers Squibb and Nektar on the PIVOT-IO-001 Phase 3 Trial Transcript
Mar 14, 2022
Q4 2021 Nektar Therapeutics Earnings Call Transcript
Feb 28, 2022

€8.71 (-3.11%)

Earnings
Nektar Therapeutics at JPMorgan Healthcare Conference (Virtual) Transcript
Jan 11, 2022
Nektar Therapeutics ESMO-IO Congress Call Transcript
Dec 06, 2021
Nektar Therapeutics Investor and Analyst Call at SITC Transcript
Nov 12, 2021
Q3 2021 Nektar Therapeutics Earnings Call Transcript
Nov 04, 2021

€14.62 (-1.42%)

Earnings
Q2 2021 Nektar Therapeutics Earnings Call Transcript
Aug 05, 2021

€13.16 (-0.60%)

Earnings
Nektar Therapeutics Annual Shareholders Meeting Transcript
Jun 10, 2021
Nektar Therapeutics at Goldman Sachs Global Healthcare Conference (Virtual) Transcript
Jun 08, 2021
Q1 2021 Nektar Therapeutics Earnings Call Transcript
May 06, 2021

€15.63 (+0.51%)

Earnings
Q4 2020 Nektar Therapeutics Earnings Call Transcript
Feb 25, 2021

€18.15 (-1.00%)

Earnings
Nektar Therapeutics at JPMorgan Healthcare Conference (Virtual) Transcript
Jan 11, 2021
Nektar Therapeutics Analysts Call with Expert Oncologist Panel During 2020 Society for Immunotherapy of Cancer (SITC) 35th Annual Meeting Transcript
Nov 11, 2020
Q3 2020 Nektar Therapeutics Earnings Call Transcript
Nov 05, 2020

€14.49 (+6.78%)

Earnings
Nektar Therapeutics Webcast Conference Call for Analysts and Investors for 2020 American College of Rheumatology (ACR) Congress Transcript
Nov 04, 2020
Nektar Therapeutics Corporate Call - COVID Analyst Event Transcript
Oct 27, 2020
Q2 2020 Nektar Therapeutics Earnings Call Transcript
Aug 06, 2020

€18.28 (+0.24%)

Earnings
Nektar Therapeutics Annual Shareholders Meeting Transcript
Jun 17, 2020
Nektar Therapeutics Conference Call for Analysts at EULAR Transcript
Jun 05, 2020
Nektar Therapeutics at Jefferies Healthcare Conference (Virtual) Transcript
Jun 03, 2020
Q1 2020 Nektar Therapeutics Earnings Call Transcript
May 07, 2020

€18.18 (+2.88%)

Earnings
Nektar Therapeutics at Cowen HealthCare Conference Transcript
Mar 03, 2020
Q4 2019 Nektar Therapeutics Earnings Call Transcript
Feb 27, 2020

€18.22 (-9.13%)

Earnings
Nektar Therapeutics at JPMorgan Healthcare Conference Transcript
Jan 13, 2020
Nektar Therapeutics at Jefferies London Healthcare Conference Transcript
Nov 20, 2019
Nektar Therapeutics Analyst and Investors Call with Melanoma Specialist During 2019 Society for Immunotherapy of Cancer 34th Annual Meeting Transcript
Nov 10, 2019
Q3 2019 Nektar Therapeutics Earnings Call Transcript
Nov 06, 2019

€16.8 (-1.18%)

Earnings
Nektar Therapeutics preliminary results from the TNBC cohort of the Ph1/2 PIVOT-02 study Transcript
Sep 26, 2019
Q2 2019 Nektar Therapeutics Earnings Call Transcript
Aug 08, 2019

€25.98 (+2.53%)

Earnings
Nektar Therapeutics Webcast Conference Call with Immunology Specialists for Analysts at EULAR Transcript
Jun 13, 2019
Q1 2019 Nektar Therapeutics Earnings Call Transcript
May 08, 2019

€29.12 (+0.76%)

Earnings
Nektar Therapeutics at Cowen Health Care Conference Transcript
Mar 12, 2019

Nektar Therapeutics Annual Shareholders Meeting Transcript

Jun 10, 2021 / 09:00PM GMT

Release Date Price: €13.86 (+2.67%)

Transcript

Mark A. Wilson

Nektar Therapeutics - Senior VP, General Counsel & Secretary

I would like to welcome everyone to Nektar Therapeutics' 2021 Annual Meeting of Stockholders. My name is Mark Wilson, Senior Vice President, General Counsel and Secretary at Nektar.

It is my pleasure to host the 2021 Annual Meeting. I will serve as Chairman and Secretary of the meeting. We are excited to be hosting this virtual meeting, which allows our stockholders to safely participate in our annual meeting. As in past years, we will conduct the business portion of our meeting first and answer questions at the end of the meeting.

Before we begin, I would like to introduce the members of our Board of Directors who are with us today: Rob Chess, the Chairman of the Board; Jeff Ajer; Myriam J. Curet; Karin Eastham; Scott Greer; Howard Robin, who is also our President and CEO; and Roy Whitfield.

Also in attendance today are certain members of Nektar's executive team. Kevin Brodbeck, Senior Vice President of Manufacturing; Gil Labrucherie, Senior Vice President, Chief Operating Officer and Chief

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.